Town & Country Bank & Trust CO dba First Bankers Trust CO Sells 200 Shares of AbbVie Inc. (NYSE:ABBV)

Town & Country Bank & Trust CO dba First Bankers Trust CO decreased its holdings in AbbVie Inc. (NYSE:ABBVFree Report) by 0.8% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 24,127 shares of the company’s stock after selling 200 shares during the quarter. AbbVie accounts for about 1.6% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings, making the stock its 17th biggest position. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in AbbVie were worth $3,251,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of ABBV. Retirement Income Solutions Inc bought a new position in shares of AbbVie during the first quarter worth approximately $204,000. Ergoteles LLC increased its stake in shares of AbbVie by 17.8% during the first quarter. Ergoteles LLC now owns 5,605 shares of the company’s stock worth $909,000 after purchasing an additional 847 shares during the period. First Western Trust Bank bought a new position in shares of AbbVie during the first quarter worth approximately $1,150,000. Wsfs Capital Management LLC bought a new position in shares of AbbVie during the first quarter worth approximately $562,000. Finally, Bridgewater Associates LP increased its stake in shares of AbbVie by 80.4% during the first quarter. Bridgewater Associates LP now owns 75,516 shares of the company’s stock worth $12,242,000 after purchasing an additional 33,661 shares during the period. Institutional investors own 67.86% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ABBV. Piper Jaffray Companies increased their target price on AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th. Piper Sandler increased their price target on AbbVie from $163.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, July 28th. TheStreet raised AbbVie from a “c+” rating to a “b” rating in a research report on Monday, August 28th. HSBC assumed coverage on AbbVie in a research report on Friday, July 14th. They set a “buy” rating and a $167.00 price target on the stock. Finally, Credit Suisse Group reduced their price target on AbbVie from $170.00 to $160.00 in a research report on Wednesday, July 12th. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $165.79.

Get Our Latest Analysis on AbbVie

AbbVie Stock Up 1.2 %

Shares of NYSE:ABBV opened at $153.93 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 0.89 and a debt-to-equity ratio of 4.33. The business has a fifty day simple moving average of $146.42 and a 200 day simple moving average of $147.44. The firm has a market cap of $271.69 billion, a P/E ratio of 31.67, a P/E/G ratio of 2.79 and a beta of 0.58. AbbVie Inc. has a 12-month low of $130.96 and a 12-month high of $168.11.

AbbVie (NYSE:ABBVGet Free Report) last issued its earnings results on Thursday, July 27th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.79 by $0.12. The company had revenue of $13.87 billion during the quarter, compared to the consensus estimate of $13.52 billion. AbbVie had a return on equity of 151.29% and a net margin of 15.50%. Analysts predict that AbbVie Inc. will post 11.03 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be paid a $1.48 dividend. The ex-dividend date is Thursday, October 12th. This represents a $5.92 annualized dividend and a dividend yield of 3.85%. AbbVie’s dividend payout ratio is presently 121.81%.

Insider Activity

In other AbbVie news, CEO Richard A. Gonzalez sold 18,500 shares of AbbVie stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $149.15, for a total transaction of $2,759,275.00. Following the completion of the transaction, the chief executive officer now owns 625,294 shares in the company, valued at approximately $93,262,600.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is currently owned by company insiders.

About AbbVie

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

See Also

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.